Prevalence of uveitis in an outpatient juvenile arthritis clinic: onset of uveitis more than a decade after onset of arthritis.
OBJECTIVE
To determine the prevalence and severity of uveitis in an outpatient pediatric arthritis clinic in the midwestern United States during the 1990s.


METHODS
The prevalence and clinical characteristics of uveitis were studied retrospectively for all children diagnosed with arthritis at Shriner's Hospital for Crippled Children and followed by the pediatric rheumatology and ophthalmology units of the St Louis Children's Hospital between 1992 and 1995.


RESULTS
Seven children (9%) developed uveitis in a population of 78 patients with juvenile arthritis. Six of the seven children were female, and all six females had anti-nuclear antibody (ANA)-positive, juvenile rheumatoid arthritis (JRA). The prevalence of anterior uveitis in females with ANA-positive, pauciarticular JRA was 20%, and in polyarticular JRA, 17%. One of the girls with uveitis had combined JRA and sarcoidosis; the boy with uveitis had juvenile spondylitis. Arthritis preceded the onset of uveitis in each child by 1 to 13 years (average, 6.4 years). Progression of the uveitis in three of the children resulted in band keratopathy and cataract, causing significant visual loss in two (i.e., in 29% of the children who developed uveitis).


CONCLUSIONS
The prevalence and ocular morbidity of uveitis in juvenile arthritis appears to have remained relatively stable over the last 2 decades. Onset of the uveitis in several of the children in our study population occurred more than a decade after the diagnosis of arthritis. Girls with ANA-positive JRA and boys with juvenile spondylitis may need to be followed by periodic slit-lamp examination for longer periods than recommended previously.
Akduman
L
L
Department of Ophthalmology, Washington University School of Medicine, St Louis, Mo., USA.
Kaplan
H J
HJ
Tychsen
L
L
D000293:Adolescent; D017668:Age of Onset; D000888:Antibodies, Anti-Idiotypic / Q000032:analysis; D000974:Antibodies, Antinuclear / Q000032:analysis; D001171:Arthritis, Juvenile / Q000150:complications* / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D015796:HLA-B27 Antigen / Q000032:analysis; D006801:Humans; D007075:Immunoglobulin M / Q000032:analysis; D008297:Male; D010044:Outpatient Clinics, Hospital; D015995:Prevalence; D012189:Retrospective Studies; D012217:Rheumatoid Factor / Q000032:analysis; D012720:Severity of Illness Index; D013166:Spondylitis / Q000150:complications; D014606:Uveitis, Anterior / Q000150:complications / Q000453:epidemiology* / Q000503:physiopathology
D000888:Antibodies, Anti-Idiotypic; D000974:Antibodies, Antinuclear; D015796:HLA-B27 Antigen; D007075:Immunoglobulin M; D012217:Rheumatoid Factor